CDMO ramp-up and battery chemicals scale are the story, with four validated products set to contribute from H2 FY27. Momentum is steady and valuation already banks it.
Overall read
6.6/10
Priced for it
The three reads · this quarter
CDMO ramp-up and battery chemicals scale are the story, with four validated products set to contribute from H2 FY27. Momentum is steady and valuation already banks it.
Overall read
6.6/10
Priced for it
The three reads · this quarter
The standing reads · change less often
Moat
Solid, defensible edge
Peer-superior 38% EBITDA on multi-route chemistry IP — STRONG tier; FY28 three-vertical thesis is the upgrade-watch.
Key variables
3 tracked
lead: Capacity utilization by siteUtilization across sites shows headroom, especially at Ankleshwar, with ramp-up expected as new products and CDMO volumes scale.
Walk the talk
Not enough data
as of Q1 FY27Battery chemicals plant commissioned, commercial supply started; capacity fully contracted, expected to reach full utilization in 3 years.
Latest · newest first
2d ago · Product & Approvals
Step-down subsidiary inaugurates semiconductor materials plant in South Korea.
1w ago · Product & Approvals
MEITY approves incentive package under ECMS scheme for the company.
24 Jul 2026 · Business Update
Press release on Q1 FY27 financial results.
03 Jul 2026 · Business Update
Designation of Senior Management Personnel approved.
2 of 2 guidance items delivered on time
Where it sits